熊去氧胆酸治疗慢性重型肝炎的疗效观察  

Efficacy of Ursodeoxycholic Acid on Chronic Severe Hepatitis

作　　者：何贵清[1] 李武[1] 段丽芳[1] 戴虹[1] 张宏丽[1] 段志文[1] 

机构地区：[1]昆明医学院第一附属医院感染科,昆明650032

出　　处：《中国现代医生》2009年第10期15-17,共3页China Modern Doctor

摘　　要：目的观察熊去氧胆酸治疗慢性重型肝炎的疗效及安全性。方法选择58例慢性重型肝炎早、中期患者,随机分为治疗组29例,对照组29例。治疗组应用UDCA及综合治疗,对照组仅用综合治疗,两组疗程均为4周。对比观察临床症状、体征及肝功能变化情况。结果治疗4周后,治疗组临床症状的改善明显优于对照组(P<0.05);治疗组在降低血清胆红素(SB)、总胆汁酸(TBA)、碱性磷酸酶(ALP)、γ-谷氨酰转肽酶(GGT)均较对照组优越(P<0.05);综合疗效的比较,治疗组显效率为41.4%,好转率为27.6%,无效率为31.0%,总有效率为69.0%,两组比较有显著性差异(P<0.05)。未观察到UDCA相关的明显不良反应。结论UDCA治疗慢性重性肝炎是安全和有效的。Objective To observe the safety and efficacy of ursodeoxycholic acid（UDCA） in the treatment of patients with chronic severe hepatitis. Methods 58 patients with chronic severe hepatitis during early stage and medium stage were randomly divided into two groups： treatmemt group in which 29 cases were treated with UDCA in addition to conventional therapy and control group in which 29 cases were only treated with conventional therapy, with a course of four weeks. The clinical symptoms, signs and liver function were compared in the two groups before treatment,2 weeks after treatment,and at the end of the treatment. Results The clinical symptoms and liver funtion：serum bilirubin （SB）, total bile acid（TBA）, alkline phosphatase（ALP） and gamma glutamyl transpeptidase（GGT）in the treatment group were improved significantly at week 4 compared to the control group（P 〈 0.05 ）. The markedly effetive rate was 41.1%, the effective rate was 27.6%, and the total effective rate was 69.0% at week 4. There was significant difference between the two groups（P〈 0.05）. No severe side-effect related to UDCA was shown. Conclusion UDCA is safe and effective in the treatment of patients with chronic severe hepatitis.

关 键 词：熊去氧胆酸 慢性重型肝炎 治疗 

分 类 号：R512.6[医药卫生—内科学]